Status:
RECRUITING
A Study of 7MW3711 in Subjects With Advanced Solid Tumors
Lead Sponsor:
Mabwell (Shanghai) Bioscience Co., Ltd.
Conditions:
Advanced Solid Tumor
Eligibility:
All Genders
18-75 years
Phase:
PHASE1
PHASE2
Brief Summary
7MW3711 is a antibody-drug conjugate(ADC) drected to a target wildly expressed on solid tumors. This is an open-label, multicenter, phase 1/2 study to evaluate the Safety, Tolerability, Pharmacokineti...
Detailed Description
Two parts are included in this study. The part of dose escalation and dose expansion(part 1) will enrolled subjects with advanced solid tumors and is to evaluate the safety and tolerability and to det...
Eligibility Criteria
Inclusion
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.
- Life expectancy of at least 3 months as assessed by the Investigator.
- Part 1: Histologically or cytologically confirmed locally advanced or metastatic solid tumor, progressive after last treatment received and who progressed on or after standard therapies or intolerant to approved therapies or who lack of effient standard therapies; part 2: Histologically or cytologically confirmed locally advanced or metastatic selected advanced solid tumors having progressed after at least one line of standard systermic therapy or intolerate standard therapies.
- An archival tumor tissue sample(formalin-fixed paraffin-embedded (FFPE) tumor tissue block or at least 5 unstained slides) or a fresh tissue sample should be provided. If the tissue sample cannot be provided during dose escalation, enrollment into the study is allowed after discussion with the Investigator
- Measurable or evaluable disease by RECIST v1.1.
- Have adequate hematopoietic, renal and hepatic functions.
- Men or women willing to use adequate contraceptive measures throughout the study
Exclusion
- Have other prior malignancies within 3 years before the first administration.
- Known central nervous system metastatic disease or carcinomatous meningitis except for treated and stable brain metastases.
- Have significant, uncontrolled, or active cardiovascular disease.
- Known history of COPD, or intestinal lung disease, or other respiratory diseases requring inpatient treatments within 4 weeks prior to first administration.
- Have adverse events due to prior antitumor therapy not resolved to grade 1 or lower by NCI CTCAE V5.0.
- have active infections requiring treatment within 14 weeks; have infection of HIV, active infection of HCV and HBV.
- Prior treatment with an antibody drug conjugate (ADC) that consists of an topoisomerase I inhibitor.
- Prior treatment with B7-H3 targeted agents.
- have received chemotherapy, immunotherapy, curative radiation within 3 weeks prior to the first administration or targeted molecular within 2 weeks prior to first administration. have received Chinese patent medicine or Chinese herbs of anti-tumor indications within 1 weeks prior to the first administration.
- Have received any systemic immunosuppressants within 2 weeks prior to the first administration except for topical corticosteroids.
- Have received any other investigational drugs or medical device within 4 weeks prior to the first administration.
- History of drug abuse including narcotic and psychiatric drugs within 12 months prior to screening.
- Pregnant, or nursing females
Key Trial Info
Start Date :
August 28 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 30 2026
Estimated Enrollment :
164 Patients enrolled
Trial Details
Trial ID
NCT06008379
Start Date
August 28 2023
End Date
January 30 2026
Last Update
September 13 2023
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Henan Cancer Hospital
Zhengzhou, Henan, China
2
Hunan Cancer Hospital
Changsha, Hunan, China
3
Xuzhou Central Hospital
Xuzhou, Jiangsu, China, 221009
4
The Lung Cancer Center of Shanghai Chest Hospital
Shanghai, Shanghai Municipality, China, 2000043